The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics

PR Newswire00:00

Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal

BenzingaOct 24 03:25

Ocuphire Pharma Is Maintained at Buy by Canaccord Genuity

Dow JonesOct 24 02:07 · Ratings

Ocuphire Pharma Analyst Ratings

BenzingaOct 24 01:57 · Ratings

Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders

BusinesswireOct 23 21:05

CCORF Maintains Ocuphire Pharma(OCUP.US) With Buy Rating, Cuts Target Price to $10

Futu NewsOct 23 20:31 · Ratings